ArticleJournal of hepato-biliary-pancreatic sciences2026
Development and Validation of Nomogram Predicting Survival in Resectable Gallbladder Cancer.
Article in Journal of hepato-biliary-pancreatic sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGallbladder cancers (GBCs) are aggressive tumors with limited improvement in outcomes over decades. Accurate prediction of survival is crucial for tailored treatment and improved outcomes.
objectiveTo develop a nomogram predicting overall survival (OS) in resectable GBCs.
methodsA retrospective analysis of 1045 patients of resected gallbladder cancer between January 2010 to December 2022 was done. A predictive nomogram was built and was internally validated.
resultsThe nomogram included age, original T stage, original N stage, and lympho-vascular/perineural invasion, CA 19.9, incidental versus non-incidental GBC, and grade. The Harrell's concordance index for the nomogram was 0.677. The area under the ROC curves for 1-, 3-, and 5-year OS were 72.12, 72.64, and 71.15 respectively. Patients were stratified into low-risk and high-risk groups based on a threshold score of 22.48, with significantly different median OS (not reached vs. 31.4 months, p < 0.001).
conclusionsThe developed nomogram demonstrates good discriminative capacity and risk stratification in patients undergoing surgery for GBC and may be utilized for better selection and application of adjuvant treatment strategies, potentially improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.